Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 98 clinical trials
Featured trial
Primary Biliary Cholangitis (PBC) Assure

People with Primary Biliary Cholangitis (PBC) are asked to participate in a research study being conducted by North Shore University Hospital. 

  • 0 views
  • 03 Aug, 2021
  • 1 location
Featured trial
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

  • 90 views
  • 25 Mar, 2021
  • 1 location
Featured trial
TARGET-PBC: A 5-year longitudinal observational study of patients with primary biliary cholangitis

TARGET-PBC: A 5-year longitudinal observational study of patients with primary biliary cholangitis

  • 129 views
  • 23 Nov, 2020
  • 1 location
Featured trial
Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC) (PiSCATIN)

cholangitis (PSC) for daily intake of 40 mg simvastatin/placebo for 5 years. The aim is to study effect of prognosis of PSC by long term intake of simvastatin. Outcome measures are death, liver

  • 4 views
  • 06 May, 2022
  • 11 locations
Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

cholangitis and suspected liver fibrosis

ursodiol
magnetic resonance cholangiopancreatography
endoscopic retrograde cholangiopancreatography
fibrosis
MRI
  • 33 views
  • 09 Jun, 2022
  • 53 locations
  • 0 views
  • 11 Aug, 2022
  • 37 locations
RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

To evaluate the treatment effect of seladelpar on composite biochemical improvement in cholestasis markers based on ALP and total bilirubin and to evaluate the safety of seladelpar over 12 months of treatment compared to placebo

  • 5 views
  • 08 Aug, 2022
  • 158 locations
Linerixibat Long-term Safety, and Tolerability Study (LLSAT)

biliary cholangitis (PBC) who participated in a prior clinical trial with linerixibat (BAT117123 [NCT01899703], 201000 GLIMMER [NCT02966834] (group 1) or 212620 GLISTEN [NCT00210418]) (group 2). All

cholestatic pruritus
cholangitis
  • 39 views
  • 15 Jul, 2022
  • 28 locations
Antibiotics to Decrease Post ERCP Cholangitis

> There is active debate whether antibiotics should be given prophylactically for ERCP outside of high risk indications including primary sclerosing cholangitis. In part this is due to a lack of

  • 10 views
  • 25 Feb, 2022
  • 1 location